blindness
(Boston) - Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
St. Jude Children's Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.
The finding points to possible new strategies to halt or prevent type I diabetes.
DURHAM, N.C. -- Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately -- because the blood thinner and antidote were designed to work together.
A new study reports that transplanted pigment-containing visual cells derived from human embryonic stem cells (hESCs) successfully preserved structure and function of the specialized light-sensitive lining of the eye (known as the retina) in an animal model of retinal degeneration.
Berlin, Germany: An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 -- ESMO 34 [1], in Berlin today (Thursday September 24).
Results: MIT engineers have designed a retinal implant for people who have lost their vision from retinitis pigmentosa or age-related macular degeneration, two of the leading causes of blindness. The retinal prosthesis would help restore some vision by electrically stimulating the nerve cells that normally carry visual input from the retina to the brain.
An international team, led by researchers from the University of California, San Diego School of Medicine and the National Eye Institute, has discovered gene variants for glaucoma in a black population. The finding could lead to future treatments or a cure for this disease, which leads to blindness in two million Americans each year.
DURHAM, N.C. -- Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.
Results: By testing formerly blind patients within weeks of sight restoration, Sinha and his colleagues found that subjects had very limited ability to distinguish an object from its background, identify overlapping objects, or even piece together the different parts of an object.
GAINESVILLE, Fla. -- Researchers from the University of Washington and the University of Florida used gene therapy to cure two squirrel monkeys of color blindness -- the most common genetic disorder in people.
BOSTON -- The virus responsible for PML (progressive multifocal leukoencephalopathy), a rare brain disease that typically affects AIDS patients and other individuals with compromised immune systems, has been found to be reactivated in multiple-sclerosis patients being treated with natalizumab (Tysabri).
NEW YORK, September 8, 2009 -- The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors -- six days per week or more -- rather than the age of patients, and that benefits continue well past the time when people with type
Rockville, MD -- By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group.
Durham, NC -- What happens when traits no longer give creatures a competitive edge?
Some subterranean animals that live in darkness function perfectly well without eyesight, for example. And the tiny leg bones buried in the backs of whales -- left over from their land-dwelling ancestors -- don't get much action in the ocean.
Lausanne, Switzerland -- Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
